Clinical Trials
3 trialsNCT02704858 2026-03-02
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
Neonc Technologies, Inc.
Phase 1/2 Recruiting
NCT05023018 2026-03-02
NEO100 and High-Grade Meningioma
Neonc Technologies, Inc.
Phase 2 Recruiting
NCT06357377 2026-01-14
A Study of the Safety, Dosing, and Delivery of NEO100 in Patients With Pediatric Brain Tumors
Neonc Technologies, Inc.
Phase 1 Not yet recruiting